Factor VII deficiency is a rare, autosomal recessive bleeding disorder marked by reduced levels or dysfunction of coagulation factor VII, a crucial initiator of the extrinsic coagulation cascade.
Pfizer disclosed a patient death in a marstacimab hemophilia study, triggering a safety review and reassessment of surgical ...
HMB-001 recognizes and binds to factor VII (FVII) protein variants associated with moderate/severe FVII deficiency and drives accumulation of endogenous FVII/FVIIa to normal ranges in in-vivo models ...
HMB-001 is currently in Phase 1/2 clinical study for Glanzmann Thrombasthenia—early research supports its potential expansion into Factor VII Deficiency COPENHAGEN, Denmark and BOSTON, June 15, 2023 ...
AN elevated prothrombin time as determined by the Quick 1 procedure may be due to many abnormalities, including deficiency of factors I (fibrinogen), II (prothrombin), V (achéal-globulin), VII ...
VON Willebrand's disease is manifested by a deficiency of factor VIII (antihemophilic factor) and a prolonged bleeding time and is inherited as an autosomal dominant trait of variable penetrance. 1 ...
LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global factor VIII deficiency treatment market is projected to grow to USD 11 billion, at a CAGR of close to 6% ...
The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback